BBIO250516P32500
- 0.00
- 0.000.00%
BridgeBio Pharma Newsroom
Bridgebio Pharma Insider Sold Shares Worth $2,558,025, According to a Recent SEC Filing
Earnings Preview: BBIO to Report Financial Results Post-market on April 29
TD Cowen Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
BridgeBio Pharma: Anticipated Q1 Outperformance and Sustained Buy Rating Despite Rising R&D Expenses
BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 Pm ET
Insider Sale: Director at $BBIO Sells 10,000 Shares
BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $53
BridgeBio Pharma Is Maintained at Buy by HC Wainwright & Co.
Express News | BridgeBio Pharma, Inc. : H.c. Wainwright Raises Target Price to $53 From $49
Press Release: BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Raymond James Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $57
BBOT Doses First Patient With BBO-11818, A PanKRAS Dual Inhibitor, In Phase 1 KONQUER-101 Trial For Advanced Solid Tumors
Redburn Atlantic Initiates BridgeBio Pharma at Buy With $50 Price Target
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
Piper Sandler Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients With Variant ATTR-CM
SA Asks: Which Small/mid-cap Cardiology Stocks Are Undervalued?